Back to News
Jan 21, 2026 8:00 AM

Johnson & Johnson Expects 2026 Sales To Hit Almost $100 Billion

Johnson & Johnson (NYSE:JNJ) on Wednesday reported a fourth-quarter 2025 adjusted earnings of $2.46 per share, up 20.6% year over year, beating the consensus of $2.44.

The pharmaceutical and medtech giant reported sales of $24.56 billion, up 9.1% year over year and beating the consensus of $24.16 billion.

Operational growth was 7.1%, and adjusted operational growth was 6.1%.

Innovative Medicine sales increased 10% or 7.9% operationally to $15.76 billion. Fiscal 2025 sales increased 6% to $60.40 billion.

2025 operational sales grew 5.3%, with net acquisitions and divestitures positively impacting growth by 1.2% primarily due to Caplyta.

Growth was ...